Trou­bled Unum re­brands as Co­gent Bio­sciences, re­places CEO Chuck Wil­son with An­drew Rob­bins; Jen­nifer Fox ap­point­ed as CFO at David Hung-led Nu­va­tion Bio

→ Rife with tur­moil and hit with a bar­rage of FDA holds as it spi­raled in­to pen­ny-stock ter­ri­to­ry, Unum Ther­a­peu­tics hopes a new name — Co­gent Bio­sciences — and a new CEO can turn its for­tunes around. An­drew Rob­bins takes con­trol now and suc­ceeds Chuck Wil­son, who found­ed Unum in 2014.

The cell ther­a­py biotech stum­bled out of the gate when it de­buted on Nas­daq in 2018 and re­vealed that 2 of its 9 pa­tients died in one arm of their AC­TR087 tri­al. The FDA would hand down 3 dif­fer­ent holds, two for AC­TR087 and an­oth­er for its ex­per­i­men­tal ther­a­py AC­TR707. Adding in­sult to in­jury, Unum shed around 60% of its work­force and jet­ti­soned its old pipeline in fa­vor of a new one a few months ago.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

Consultant

Recon Strategy

Boston, MA, USA